- Home
- RPID
as of 04-10-2026 3:40pm EST
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 204.3M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 281.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | 2.78 |
| 52 Week Low/High: | $2.00 - $4.94 | Next Earning Date: | 05-08-2026 |
| Revenue: | $33,587,000 | Revenue Growth: | 19.74% |
| Revenue Growth (this year): | 19.12% | Revenue Growth (next year): | 18.42% |
| P/E Ratio: | -2.02 | Index: | N/A |
| Free Cash Flow: | -31912000.0 | FCF Growth: | N/A |
AI-Powered RPID Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Rapid Micro Biosystems Inc. (RPID)
CHIEF OPERATING OFFICER
Avg Cost/Share
$4.32
Shares
9,603
Total Value
$41,466.71
Owned After
316,762
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$4.32
Shares
7,480
Total Value
$32,299.39
Owned After
556,194
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$4.11
Shares
17,922
Total Value
$73,686.30
Owned After
1,169,848
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$3.78
Shares
4,610
Total Value
$17,438.25
Owned After
316,762
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$3.78
Shares
6,027
Total Value
$22,798.33
Owned After
556,194
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$3.78
Shares
12,840
Total Value
$48,569.87
Owned After
1,169,848
SEC Form 4
10% Owner
Avg Cost/Share
$3.88
Shares
49,000
Total Value
$190,090.60
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$4.24
Shares
27,500
Total Value
$116,641.25
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$4.25
Shares
27,500
Total Value
$116,765.00
Owned After
0
SEC Form 4
10% Owner
Avg Cost/Share
$4.54
Shares
46,000
Total Value
$209,001.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Wilson John J. Addington | RPID | CHIEF OPERATING OFFICER | Mar 11, 2026 | Sell | $4.32 | 9,603 | $41,466.71 | 316,762 | |
| WIRTJES SEAN M | RPID | CHIEF FINANCIAL OFFICER | Mar 11, 2026 | Sell | $4.32 | 7,480 | $32,299.39 | 556,194 | |
| Spignesi Robert G. Jr. | RPID | PRESIDENT AND CEO | Mar 10, 2026 | Sell | $4.11 | 17,922 | $73,686.30 | 1,169,848 | |
| Wilson John J. Addington | RPID | CHIEF OPERATING OFFICER | Feb 9, 2026 | Sell | $3.78 | 4,610 | $17,438.25 | 316,762 | |
| WIRTJES SEAN M | RPID | CHIEF FINANCIAL OFFICER | Feb 9, 2026 | Sell | $3.78 | 6,027 | $22,798.33 | 556,194 | |
| Spignesi Robert G. Jr. | RPID | PRESIDENT AND CEO | Feb 9, 2026 | Sell | $3.78 | 12,840 | $48,569.87 | 1,169,848 | |
| Longitude Capital Partners II, LLC | RPID | 10% Owner | Feb 4, 2026 | Sell | $3.88 | 49,000 | $190,090.60 | 0 | |
| Longitude Capital Partners II, LLC | RPID | 10% Owner | Feb 3, 2026 | Sell | $4.24 | 27,500 | $116,641.25 | 0 | |
| Longitude Capital Partners II, LLC | RPID | 10% Owner | Feb 2, 2026 | Sell | $4.25 | 27,500 | $116,765.00 | 0 | |
| Longitude Capital Partners II, LLC | RPID | 10% Owner | Jan 30, 2026 | Sell | $4.54 | 46,000 | $209,001.00 | 0 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYMar 12, 2026 · 100% conf.
1D
+1.49%
$3.12
Act: +19.87%
5D
+14.00%
$3.50
Act: +50.16%
20D
+42.50%
$4.37
Act: +36.81%
rpid-202603120001380106false00013801062026-03-122026-03-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2026
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4059220-8121647 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.) 25 Hartwell Avenue, Lexington, MA 02421
(Address of principal executive offices) (Zip Code)
978-349-3200 (Registrant’s telephone number, including area code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolsName of each exchange on which registered Class A Common Stock, $0.01 par value per shareRPIDThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company þ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On March 12, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
Item 7.01 Regulation FD Disclosure.
On March 12, 2026, the Company issued a press release announcing a new multi-system order from Samsung Biologics for its Growth Direct platform. A copy of the press release is furnished herewith as Exhibit 99.2 and is incorporated herein by this reference. The information furnished under Items 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1 Press Release of Rapid Micro Biosystems, Inc., dated March 12, 2026, related to its financial results for its fourth quarter and fiscal year ended December 31, 2025.
99.2 Press Release of Rapid Micro Biosystems, Inc., dated March 12, 2026
104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: March 12, 2026By:/s/ Sean Wirtjes Sean Wirtjes Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 13, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 13, 2026 · 100% conf.
1D
+1.49%
$3.12
Act: +19.87%
5D
+14.00%
$3.50
Act: +50.16%
20D
+42.50%
$4.37
Act: +36.81%
rpid-202601130001380106false00013801062026-01-132026-01-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2026
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4059220-8121647 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.) 25 Hartwell Avenue, Lexington, MA 02421
(Address of principal executive offices) (Zip Code)
978-349-3200 (Registrant’s telephone number, including area code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolsName of each exchange on which registered Class A Common Stock, $0.01 par value per shareRPIDThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company þ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On January 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1 Press Release of Rapid Micro Biosystems, Inc., dated January 13, 2026.
104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: January 13, 2026By:/s/ Sean Wirtjes Sean Wirtjes Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 7, 2025
Q3 2025 Earnings
8-KNov 7, 2025
rpid-202511070001380106false00013801062025-11-072025-11-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2025
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4059220-8121647 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.) 25 Hartwell Avenue, Lexington, MA 02421
(Address of principal executive offices) (Zip Code)
978-349-3200 (Registrant’s telephone number, including area code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolsName of each exchange on which registered Class A Common Stock, $0.01 par value per shareRPIDThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company þ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On November 7, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description 99.1 Press Release of Rapid Micro Biosystems, Inc., dated November 7, 2025, related to its financial results for its third quarter ended September 30, 2025.
104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: November 7, 2025By:/s/ Sean Wirtjes Sean Wirtjes Chief Financial Officer
Compare RPID vs Leading Stocks
See how RPID stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RPID Rapid Micro Biosystems Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.